Learn how the complex signaling features of these receptors ... and this hormone binds to glucagon receptors in the liver. This binding stimulates breakdown of glycogen and the release of glucose ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

Announcing a new article publication for BIO Integration journal.   Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A systematic review of 26 randomized controlled trials (RCTs) finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated ...